Summary of Study ST000502

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000379. The data can be accessed directly via it's Project DOI: 10.21228/M82C8B This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files
Study IDST000502
Study TitleWeight loss and weight maintenance obtained with or without GLP-1 analogue treatment decrease branched chain amino acid levels.
Study TypeRCT
Study SummaryRCT of the effect og liraglutide on weight maintenance. 58 individuals wer included and subjected to low calorie intake during 8 weeks. Individuals lost a mean of 12 kg during that period. Individuals were then randomized to receive 1.2 mg liraglutide daily for 1 year or serving as control. Metabolites were measured at inclusion (-8 weeks), randomization (0 weeks) and at 4 and 52 weeks during weight maintenance.
Institute
NNF Center for Metabolic Research
Last NameEngelbrechtsen
First NameLine
AddressSection of Metabolic Genetics, Universitetsparken 1, DIKU building 1st floor, 2100 Copenhagen
Emailline@sund.ku.dk
Phone+4535333639
Submit Date2016-11-02
Num Groups2
Total Subjects58
Analysis Type DetailNMR
Release Date2016-12-22
Release Version1
Line Engelbrechtsen Line Engelbrechtsen
https://dx.doi.org/10.21228/M82C8B
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR000379
Project DOI:doi: 10.21228/M82C8B
Project Title:Weight loss and weight maintenance obtained with or without GLP-1 analogue treatment decrease branched chain amino acid levels
Project Type:NMR
Project Summary:RCT on the effect of liraglutide on weight maintenance during 1 year
Institute:University of Copenhagen
Department:Section of Novo Nordisk Foundation Center for Basic Metabolic Research;Section of Metabolic Genetics;Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen
Last Name:Engelbrechtsen
First Name:Line
Address:Section of Metabolic Genetics, Universitetsparken 1, DIKU building 1st floor, 2100 Copenhagen
Email:line@sund.ku.dk
Phone:+4535333639
Funding Source:The study incl. purchase of Victoza pens was supported by funding from The Danish Research Council for Health and Disease (ref. no: 11-107683), the University Investment Capital (UNIK): Food, Fitness & Pharma for Health and Disease from the Danish Ministry of Science, Technology and Innovation and the Danish Diabetes Academy funded by the Novo Nordisk Foundation. Cambridge Weight Plan products were donated from Cambridge Weight Plan.

Subject:

Subject ID:SU000524
Subject Type:Humans
Subject Species:Homo sapiens
Taxonomy ID:9606
Species Group:Human

Factors:

Subject type: Humans; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Time(weeks) Treatment
SA0260994_294 Control
SA0261004_284 Control
SA0261014_264 Control
SA0261024_514 Control
SA0261034_244 Control
SA0261044_464 Control
SA0261054_224 Control
SA0261064_404 Control
SA0261074_354 Control
SA0261084_344 Control
SA0261094_494 Control
SA0261104_114 Control
SA0261114_84 Control
SA0261124_214 Control
SA0261134_74 Control
SA0261144_584 Control
SA0261154_14 Control
SA0261164_124 Control
SA0261174_424 Control
SA0261184_544 Control
SA0261194_204 Control
SA0261204_154 Control
SA0261214_444 GLP-1 analogue
SA0261224_524 GLP-1 analogue
SA0261234_434 GLP-1 analogue
SA0261244_454 GLP-1 analogue
SA0261254_534 GLP-1 analogue
SA0261264_504 GLP-1 analogue
SA0261274_484 GLP-1 analogue
SA0261284_574 GLP-1 analogue
SA0261294_474 GLP-1 analogue
SA0261304_174 GLP-1 analogue
SA0261314_234 GLP-1 analogue
SA0261324_144 GLP-1 analogue
SA0261334_54 GLP-1 analogue
SA0261344_394 GLP-1 analogue
SA0261354_24 GLP-1 analogue
SA0261364_254 GLP-1 analogue
SA0261374_104 GLP-1 analogue
SA0261384_274 GLP-1 analogue
SA0261394_384 GLP-1 analogue
SA0261404_374 GLP-1 analogue
SA0261414_364 GLP-1 analogue
SA0261424_304 GLP-1 analogue
SA0261434_314 GLP-1 analogue
SA0261444_334 GLP-1 analogue
SA02614552_2952 Control
SA02614652_4652 Control
SA02614752_4152 Control
SA02614852_1552 Control
SA02614952_2852 Control
SA02615052_3452 Control
SA02615152_4252 Control
SA02615252_2252 Control
SA02615352_2152 Control
SA02615452_2052 Control
SA02615552_5852 Control
SA02615652_652 Control
SA02615752_2652 Control
SA02615852_352 Control
SA02615952_152 Control
SA02616052_752 Control
SA02616152_852 Control
SA02616252_4052 Control
SA02616352_1252 Control
SA02616452_1152 Control
SA02616552_3952 GLP-1 analogue
SA02616652_5752 GLP-1 analogue
SA02616752_5252 GLP-1 analogue
SA02616852_3852 GLP-1 analogue
SA02616952_4852 GLP-1 analogue
SA02617052_4752 GLP-1 analogue
SA02617152_4452 GLP-1 analogue
SA02617252_4552 GLP-1 analogue
SA02617352_4352 GLP-1 analogue
SA02617452_1852 GLP-1 analogue
SA02617552_1452 GLP-1 analogue
SA02617652_1652 GLP-1 analogue
SA02617752_1052 GLP-1 analogue
SA02617852_952 GLP-1 analogue
SA02617952_252 GLP-1 analogue
SA02618052_552 GLP-1 analogue
SA02618152_1752 GLP-1 analogue
SA02618252_1952 GLP-1 analogue
SA02618352_3052 GLP-1 analogue
SA02618452_3652 GLP-1 analogue
SA02618552_2752 GLP-1 analogue
SA02618652_2552 GLP-1 analogue
SA02618752_2352 GLP-1 analogue
SA02618852_3752 GLP-1 analogue
SA025996-8_26-8 Control
SA025997-8_49-8 Control
SA025998-8_24-8 Control
SA025999-8_51-8 Control
SA026000-8_22-8 Control
SA026001-8_28-8 Control
SA026002-8_40-8 Control
SA026003-8_29-8 Control
SA026004-8_42-8 Control
SA026005-8_41-8 Control
Showing page 1 of 2     Results:    1  2  Next     Showing results 1 to 100 of 193

Collection:

Collection ID:CO000518
Collection Summary:The samples analyzed were obtained in a fasting state. Samples were taken at inclusion, after 8 weeks of weight loss (baseline), and after 4 and 52 weeks of weight maintenance.
Collection Protocol ID:ClinicalTrials.gov Identifier: NCT02094183
Sample Type:Blood

Treatment:

Treatment ID:TR000538
Treatment Summary:22 indivuals received 1.2 mg of liraglutide injections (Victoza, Novo Nordisk)daily for 1 year, 20 controls did not receive treatment

Sample Preparation:

Sampleprep ID:SP000531
Sampleprep Summary:Prior to the NMR measurements, 260 μL of EDTA plasma and 260 μL of a sodium phosphate buffer (75 mmol/L Na2HPO4 in 80%/20% H2O/D2O, pH 7.4; including also 0.08% sodium 3-(trimethylsilyl)propionate-2,2,3,3-d4 and 0.04% sodium azide) was mixed and moved to the NMR tubes. All the liquid handling steps for plasma samples were done with a PerkinElmer JANUS Automated Workstation. The NMR metabolomics laboratory setup combined Bruker AVANCE III 500 MHz and Bruker AVANCE III HD 600 MHz spectrometers

Analysis:

Analysis ID:AN000771
Analysis Type:NMR
Num Factors:8
Num Metabolites:12
Units:mmol/l

NMR:

NMR ID:NM000091
Analysis ID:AN000771
Instrument Name:Bruker Avance III 500 MHz and Bruker AVANCE III HD 600 MHz
Instrument Type:FT-NMR
NMR Experiment Type:1D 1H
Spectrometer Frequency:500 and 600 MHz
  logo